Incannex Healthcare Inc.

IXHL Nasdaq CIK: 0001873875

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Country Australia
Business Address 8 CENTURY CIRCUIT, NORWEST NSW, ,
Mailing Address 8 CENTURY CIRCUIT, NORWEST NSW, ,
Phone 61 409 840 786
Fiscal Year End 0630
EIN 000000000

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 27, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
8-K Current report of material events March 18, 2026 View on SEC
8-K Current report of material events March 17, 2026 View on SEC
424B5 Prospectus supplement March 12, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
8-K Current report of material events February 25, 2026 View on SEC
10-Q Quarterly financial report February 13, 2026 View on SEC
8-K Current report of material events January 29, 2026 View on SEC

Annual Reports

10-K September 29, 2025
  • Advanced clinical trials including Phase 3 for sleep apnea treatment
  • Partnered with a top research university to boost credibility
View Analysis

Material Events

8-K Strategy Change March 17, 2026
High Impact
  • Incannex Healthcare Inc. has regained full compliance with Nasdaq's listing requirements, ensuring its continued listing on the Nasdaq Capital Market.
  • The company implemented a 1-for-10 reverse stock split to meet the minimum bid price requirement, removing the immediate threat of delisting.
View Analysis
8-K Strategy Change February 25, 2026
High Impact
  • Incannex Healthcare Inc. will implement a 1-for-30 reverse stock split to consolidate shares.
  • The primary goal is to regain and maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.